Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. Among authors: tong s. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X, Xu H, Chen X, Xu T, Tian Y, Wang D, Guo F, Wang K, Jin G, Li X, Wang R, Li F, Ding Y, Tang J, Fang Y, Zhao J, Liu L, Ma L, Meng L, Hou Z, Zheng R, Liu Y, Guan N, Zhang B, Tong S, Chen S, Li X, Shu Y. Chen X, et al. Among authors: tong s. Signal Transduct Target Ther. 2024 Mar 25;9(1):73. doi: 10.1038/s41392-024-01773-9. Signal Transduct Target Ther. 2024. PMID: 38528050 Free PMC article. Clinical Trial.
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Vale CL, Godolphin PJ, Fisher DJ, Higgins JPT, McAleenan A, Spiga F, Tritschler T, de Barros E Silva PGM, Berg DD, Berger JS, Berry LR, Bikdeli B, Blondon M, Bohula EA, Cattaneo M, Colombo R, Coluccio V, DeSancho MT, Farkouh ME, Fuster V, Girardis M, Hochman JS, Jensen TP, Jha V, Jüni P, Kirtane AJ, Lawler P, Le Gal G, Lecumberri R, Lentz SR, Lopes RD, Lorenzi E, Marietta M, Miranda CH, Morici N, Morpeth SC, Morrow DA, McQuilten ZK, Muñoz-Rivas N, Neal MD, Pant S, Parikh SA, Perepu U, Sadeghipour P, Sethi S, Sholzberg M, Spyropoulos AC, Stone GW, Talasaz AH, Tong S, Totterdell J, Venkatesh B, Wu MA, Zarychanski R, Zuily S, Viry J, Rylance J, Adhikari NKJ, Diaz JV, Marshall JC, Sterne JAC, Murthy S. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Among authors: tong s. Ann Intern Med. 2024 Dec 24. doi: 10.7326/ANNALS-24-00800. Online ahead of print. Ann Intern Med. 2024. PMID: 39715559 Review.
3,736 results